Rocket Pharmaceuticals (RCKT) Total Liabilities (2014 - 2026)

Rocket Pharmaceuticals has reported Total Liabilities for 13 years, with the latest figure at $47.4 million in Q1 2026.

• Quarterly Total Liabilities fell 19.62% year-over-year to $47.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.4 million (down 19.62% YoY) and the FY2025 annual result came in at $53.2 million, down 17.43% from the prior year.
• Total Liabilities fell to $47.4 million in Q1 2026 per RCKT's latest filing, from $53.2 million in the prior quarter.
• Over five years, Total Liabilities peaked at $73.8 million in Q4 2023 and troughed at $42.5 million in Q1 2022.
• A 5-year average of $57.3 million and a median of $57.9 million in 2024 frame the typical range for Total Liabilities.
• The widest YoY moves for Total Liabilities: up 46.87% in 2022, down 55.92% in 2022.
• Over 5 years, Total Liabilities stood at $62.1 million in 2022, then gained by 18.75% to $73.8 million in 2023, then declined by 12.61% to $64.5 million in 2024, then slipped by 17.43% to $53.2 million in 2025, then declined by 11.01% to $47.4 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $47.4 million, $53.2 million, and $54.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.